Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selmaj, K. W.
Right arrow Articles by Raine, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selmaj, K. W.
Right arrow Articles by Raine, C. S.

Neurology, Vol 45, Issue 6 S44-S49, Copyright © 1995 by American Academy of Neurology

ARTICLES

Experimental autoimmune encephalomyelitis: immunotherapy with anti- tumor necrosis factor antibodies and soluble tumor necrosis factor receptors

KW Selmaj and CS Raine
Department of Neurology, Medical Academy of Lodz, Poland.

Multiple sclerosis (MS) is a demyelinating disease in which an inflammatory cell infiltrate represents a characteristic pathologic feature of active lesions within the CNS. The possibility has been raised that cell-mediated immune mechanisms orchestrate the pathogenesis of MS. Cytokines play a particularly important role in cellular immune mechanisms. These soluble glycoproteins, nonimmunoglobulin in nature, act nonenzymatically to regulate immune cell function. A unique family of cytokines, the tumor necrosis factors (TNFs), demonstrate immunoregulatory activity but are also involved in the effector arm of cellular immune responses. Recently, studies both in vitro and in vivo have suggested a role for TNFs in the pathology of MS. This report summarizes data implicating TNFs in the mechanisms of MS and attempts to apply the anti-TNF approach in the future therapeutic strategy for this disease.


This article has been cited by other articles:


Home page
 BrainHome page
M. Matysiak, A. Jurewicz, D. Jaskolski, and K. Selmaj
TRAIL induces death of human oligodendrocytes isolated from adult brain
Brain, November 1, 2002; 125(11): 2469 - 2480.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
N. L. Sicotte and R. R. Voskuhl
Onset of multiple sclerosis associated with anti-TNF therapy
Neurology, November 27, 2001; 57(10): 1885 - 1888.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. E. Smith, N. L. Eller, H. F. McFarland, M. K. Racke, and C. S. Raine
Age Dependence of Clinical and Pathological Manifestations of Autoimmune Demyelination : Implications for Multiple Sclerosis
Am. J. Pathol., October 1, 1999; 155(4): 1147 - 1161.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
N. Rajora, G. Boccoli, D. Burns, S. Sharma, A. P. Catania, and J. M. Lipton
alpha -MSH Modulates Local and Circulating Tumor Necrosis Factor-alpha in Experimental Brain Inflammation
J. Neurosci., March 15, 1997; 17(6): 2181 - 2186.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.